MA38473B1 - (2-aza-bicyclo [2.2.1] heptane-3-carboxylic acid (substituted benzyl-cyano-methyl) -amides used as inhibitors of - Google Patents

(2-aza-bicyclo [2.2.1] heptane-3-carboxylic acid (substituted benzyl-cyano-methyl) -amides used as inhibitors of

Info

Publication number
MA38473B1
MA38473B1 MA38473A MA38473A MA38473B1 MA 38473 B1 MA38473 B1 MA 38473B1 MA 38473 A MA38473 A MA 38473A MA 38473 A MA38473 A MA 38473A MA 38473 B1 MA38473 B1 MA 38473B1
Authority
MA
Morocco
Prior art keywords
aza
bicyclo
heptane
cyano
inhibitors
Prior art date
Application number
MA38473A
Other languages
French (fr)
Other versions
MA38473A1 (en
Inventor
Stefan Peters
Thorsten Oost
Ralf Anderskewitz
Matthias Grauert
Marc Grundl
Peter Wilhelm Haebel
Alexander Pautsch
Florian Binder
Viktor Vintonyak
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2014/054794 external-priority patent/WO2014140075A1/en
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA38473A1 publication Critical patent/MA38473A1/en
Publication of MA38473B1 publication Critical patent/MA38473B1/en

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des (benzyl-cyano-méthyl)-amides de l'acide 2-aza-bicyclo[2.2.1]heptane-3-carboxylique de formule (1) et leur utilisation comme inhibiteurs de la cathépsine c, des compositions pharmaceutiques contenant ceux-ci, et des méthodes d'utilisation de ceux-ci comme agents pour le traitement et/ou la prévention de maladies associées à l'activité de la dipeptidyl peptidase i, par exemple des maladies respiratoires.The present invention relates to (benzyl-cyano-methyl) -amides of 2-aza-bicyclo [2.2.1] heptane-3-carboxylic acid of formula (1) and their use as cathepsin-c inhibitors, compositions pharmaceutical compositions containing these, and methods of use thereof as agents for the treatment and / or prevention of diseases associated with the activity of dipeptidyl peptidase i, for example respiratory diseases.

MA38473A 2013-03-14 2015-10-09 (2-aza-bicyclo [2.2.1] heptane-3-carboxylic acid (substituted benzyl-cyano-methyl) -amides used as inhibitors of MA38473B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13159240 2013-03-14
PCT/EP2014/054794 WO2014140075A1 (en) 2013-03-14 2014-03-12 Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c

Publications (2)

Publication Number Publication Date
MA38473A1 MA38473A1 (en) 2016-04-29
MA38473B1 true MA38473B1 (en) 2016-11-30

Family

ID=47845866

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38473A MA38473B1 (en) 2013-03-14 2015-10-09 (2-aza-bicyclo [2.2.1] heptane-3-carboxylic acid (substituted benzyl-cyano-methyl) -amides used as inhibitors of

Country Status (2)

Country Link
AR (1) AR095376A1 (en)
MA (1) MA38473B1 (en)

Also Published As

Publication number Publication date
AR095376A1 (en) 2015-10-14
MA38473A1 (en) 2016-04-29

Similar Documents

Publication Publication Date Title
PH12015501964B1 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
MA38483A1 (en) Inhibitors of ido
MA38380A1 (en) Quinazoline inhibitors of activation of mutant forms of epidermal growth receptor (EGFR)
MA37762B1 (en) N-aryltriazole compounds used as antagonists of lpar
MA44948A1 (en) Bace 1 inhibitors
MA37764A1 (en) N-alkyltriazole compounds used as antagonists of lpar
MA35459B1 (en) Compounds and compositions that can be used as c-kit kinase inhibitors
MA41179A (en) PARG INHIBITOR COMPOUNDS
MA39219B1 (en) New lrrk2 Kinase Inhibitor Compounds Used to Treat Parkinson's, Alzheimer's and Amyotrophic Lateral Sclerosis
MA35638B1 (en) 2-thiopyrimidinones
MA38810A1 (en) Inhibitors of rorc2 related methods of use
MA37691B1 (en) 5-amino [1,4] thiazines as bace1 inhibitors
MA37763A1 (en) Difluoro-hexahydro-cyclopentaoxazinyl and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
MA37742A1 (en) Derivatives of 3-substituted oestra-1,3,5 (10), 16-tetraene, processes for their preparation, pharmaceutical preparations containing them, and their use in the manufacture of medicaments
MA37765A1 (en) Substituted pyrazole compounds used as lpar antagonists
MA43052B1 (en) Human Plasma Kallikrein Inhibitors
MA38473B1 (en) (2-aza-bicyclo [2.2.1] heptane-3-carboxylic acid (substituted benzyl-cyano-methyl) -amides used as inhibitors of
MA39260A1 (en) (2-aza-bicyclo [2.2.1] heptane-3-carboxylic acid (substituted benzyl-cyano-methyl) -amides used as inhibitors of
MA39533B1 (en) Compounds, pharmaceutical composition and their use in the treatment of neurodegenerative diseases
MA56098B1 (en) HETEROCYCLIC IMMUNOMODULATORS AS WELL AS PDL1 INHIBITORS
MA43263B1 (en) Heterocyclic compounds used as immunomodulators
MA45867B1 (en) Estrogen receptor modulators
MA44144A (en) HETEROCYCLIC COMPOUNDS USED AS IMMUNOMODULATORS
MA35894B1 (en) Oxazolidin-2-one compounds and uses thereof as pi3k inhibitors
FR3042191B1 (en) 1,4,8-TRIAZAPHENANTHRENE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES